Ortho-DOT

Ortho-DOT
Clinical data
Other nameso-DOT; 4,5-Dimethoxy-2-methylthioamphetamine; 2-Methylthio-4,5-dimethoxyamphetamine; 2-Thio-TMA-2
Routes of
administration
Oral[1]
Drug classPsychoactive drug
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • 1-[4,5-dimethoxy-2-(methylsulfanyl)phenyl]propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H19NO2S
Molar mass241.35 g·mol−1
3D model (JSmol)
  • S(c1cc(OC)c(OC)cc1CC(N)C)C
  • InChI=1S/C12H19NO2S/c1-8(13)5-9-6-10(14-2)11(15-3)7-12(9)16-4/h6-8H,5,13H2,1-4H3 Y
  • Key:GQUWSNDODZTHKC-UHFFFAOYSA-N Y
  (verify)

Ortho-DOT, also known as 4,5-dimethoxy-2-methylthioamphetamine or as 2-thio-TMA-2, is a psychoactive drug of the phenethylamine and amphetamine families related to TMA-2.[1][2] It is the analogue of TMA-2 in which the methoxy group at the 2 position has been replaced with a methylthio group.[1][2] In addition, the drug is a positional isomer of Aleph (DOT; para-DOT).[1][2]

In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists ortho-DOT's dose as greater than 25 mg orally and its duration as unknown.[1][2] The effects of ortho-DOT have been reported to include threshold effects, vague awareness, a feeling of an impending something, and gastrointestinal disturbance.[1] No clear hallucinogenic effects were described.[1] Shulgin concluded that ortho-DOT was inactive.[2] Higher doses were not tested.[1]

Ortho-DOT has been found to produce hyperthermia in rabbits, albeit with approximately 50-fold lower potency than DOM, though with somewhat greater potency than mescaline.[1][3][4]

The chemical synthesis of ortho-DOT has been described.[1][3] Analogues of ortho-DOT include TMA-2, Aleph (DOT; para-DOT; 4-thio-TMA-2), meta-DOT (5-thio-TMA-2), 2-TOM (2-thio-DOM), and 2-TOET (2-thio-DOET), among others.[1][2]

Ortho-DOT was first described in the scientific literature by Shulgin and colleagues in 1977.[3] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1]

See also

References

  1. ^ a b c d e f g h i j k l m Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. Ortho-DOT entry
  2. ^ a b c d e f Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025. The two other possible oxygen substitutions of DOT have been synthesized and evaluated; this completes the three theoretical thio-analogues of TMA-2. 4,5-Dimethoxy-2-methylthioamphetamine and 2,4-dimethoxy-5-methylthioam-phetamine (Ortho-DOT and Meta-DOT respectively) were without any central effects at levels of 25mg orally.
  3. ^ a b c Jacob P, Anderson G, Meshul CK, Shulgin AT, Castagnoli N (October 1977). "Monomethylthio analogues of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane". J Med Chem. 20 (10): 1235–1239. doi:10.1021/jm00220a001. PMID 903913. Archived from the original on 2025-07-12.
  4. ^ Anderson GM, Castagnoli N, Kollman PA (1978). "Quantitative structure-activity relationships in the 2,4,5-ring substituted phenylisopropylamines". NIDA Res Monogr (22): 199–217. PMID 101881.